Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

166
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
166
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

1.3K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.3K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

539
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
539
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

151
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
151
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

645
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
645
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

66
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
66

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Point of Care UCHL1/GFAP for Rapid Assessment of Undifferentiated Trauma Patients.

Journal of the American College of Surgeons·2026
Same author

Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage.

The New England journal of medicine·2026
Same author

Impact of Heating Inspired Gases During Mechanical Ventilation on Resolution of Hypothermia in a Porcine Model.

Respiratory care·2026
Same author

Microvesicles in stored human whole blood increase thrombin generation via phosphatidylserine.

The journal of trauma and acute care surgery·2026
Same author

Making the House a Home: Cultivating Community in Surgery.

Annals of surgery·2026
Same author

Evaluating Cryopreserved and Liquid-Stored Platelets for Bleeding During Cardiac Surgery.

JAMA surgery·2026

Related Experiment Video

Updated: Nov 7, 2025

How to Administer Near-Infrared Spectroscopy in Critically ill Neonates, Infants, and Children
07:27

How to Administer Near-Infrared Spectroscopy in Critically ill Neonates, Infants, and Children

Published on: August 19, 2020

11.9K

Hitting the Vasopressor Ceiling: Finding Norepinephrine Associated Mortality in the Critically Ill.

Kathleen E Singer1, Jonathan E Sussman1, Resha A Kodali1

  • 1Department of General Surgery, University of Cincinnati, Cincinnati Ohio.

The Journal of Surgical Research
|May 3, 2021
PubMed
Summary

Norepinephrine dosing thresholds for futility in intensive care units (ICUs) were identified. Medical ICU patients tolerated higher doses than surgical ICU patients, with trauma patients showing increased mortality even at low doses.

More Related Videos

A Rat Model of Ventricular Fibrillation and Resuscitation by Conventional Closed-chest Technique
09:47

A Rat Model of Ventricular Fibrillation and Resuscitation by Conventional Closed-chest Technique

Published on: April 26, 2015

16.1K
Large-Animal Model of Donation after Circulatory Death and Normothermic Regional Perfusion for Cardiac Assessment
07:49

Large-Animal Model of Donation after Circulatory Death and Normothermic Regional Perfusion for Cardiac Assessment

Published on: May 10, 2022

1.8K

Related Experiment Videos

Last Updated: Nov 7, 2025

How to Administer Near-Infrared Spectroscopy in Critically ill Neonates, Infants, and Children
07:27

How to Administer Near-Infrared Spectroscopy in Critically ill Neonates, Infants, and Children

Published on: August 19, 2020

11.9K
A Rat Model of Ventricular Fibrillation and Resuscitation by Conventional Closed-chest Technique
09:47

A Rat Model of Ventricular Fibrillation and Resuscitation by Conventional Closed-chest Technique

Published on: April 26, 2015

16.1K
Large-Animal Model of Donation after Circulatory Death and Normothermic Regional Perfusion for Cardiac Assessment
07:49

Large-Animal Model of Donation after Circulatory Death and Normothermic Regional Perfusion for Cardiac Assessment

Published on: May 10, 2022

1.8K

Area of Science:

  • Critical Care Medicine
  • Pharmacology
  • Clinical Research

Background:

  • Norepinephrine is a vasopressor used in critical care.
  • Optimal dosing strategies for norepinephrine remain unclear.
  • Defining futility in vasopressor support is essential for patient outcomes.

Purpose of the Study:

  • To determine maximum infusion and cumulative doses of norepinephrine associated with survival.
  • To investigate dose-response relationships in medical and surgical intensive care units (MICU and SICU).

Main Methods:

  • Retrospective review of 661 critically ill patients receiving norepinephrine.
  • Univariate, multivariate, and AUC analyses to identify optimal dose cutoffs.
  • Youden Index used for determining maximum infusion rate and cumulative dosage.

Main Results:

  • Mortality inflection points identified at 18 mcg/min and 17.6 mg of norepinephrine.
  • MICU patients had higher inflection points (21 mcg/min, 30.7 mg) than SICU patients (11 mcg/min, 2.7 mg).
  • Trauma patients receiving up to 5 mcg/min had a 41.7% mortality rate.

Conclusions:

  • Maximum norepinephrine rates of 18 mcg/min and cumulative doses of 17.6 mg are mortality inflection points in ICUs.
  • Surgical ICU patients tolerate lower norepinephrine doses than medical ICU patients.
  • Trauma patients exhibit increased mortality risk even with low-dose norepinephrine, indicating differential responses across patient populations.